2 weeks Ago By ABMN Staff
HB Wealth Management LLC lifted its stake in Biogen Inc. ( NASDAQ:BIIB – Free Report ) by 20.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission.
The fund owned 1,983 shares of the biotechnology company’s stock after buying an additional 338 shares during the quarter. HB Wealth Management LLC’s holdings in Biogen were worth $460,000 as of its most recent SEC filing. Several other hedge funds and other institutional investors have also recently bought and sold shares of BIIB.
Vanguard Group Inc. boosted its position in Biogen by 18.2% in the 4th quarter.
Vanguard Group Inc. now owns 14,407,330 shares of the biotechnology company’s stock worth $3,728,185,000 after purchasing an additional 2,218,744 shares in the last quarter. Norges Bank purchased a new position in Biogen in the fourth quarter valued at $378,728,000.
FIL Ltd grew its position in shares of Biogen by 936.4% during the 4th quarter. FIL Ltd now owns 656,502 shares of the biotechnology company’s stock valued at $169,883,000 after acquiring an additional 593,158 shares during the period.
First Trust Advisors LP increased its stake in shares of Biogen by 141.0% in the 4th quarter. First Trust Advisors LP now owns 977,308 shares of the biotechnology company’s stock valued at $252,898,000 after purchasing an additional 571,795 shares in the last quarter.
Finally, Van ECK Associates Corp raised its holdings in Biogen by 22.2% in the 1st quarter. Van ECK Associates Corp now owns 1,737,340 shares of the biotechnology company’s stock worth $374,623,000 after purchasing an additional 316,144 shares during the period.
87.93% of the stock is owned by institutional investors and hedge funds. Biogen Price Performance BIIB stock opened at $204.
82 on Friday. The business’s fifty day moving average price is $216.53 and its 200 day moving average price is $217.
59. Biogen Inc. has a 12-month low of $189.
44 and a 12-month high of $270.50. The company has a market capitalization of $29.
82 billion, a PE ratio of 25.57, a P/E/G ratio of 2.09 and a beta of -0.
04. The company has a current ratio of 2.29, a quick ratio of 1.
32 and a debt-to-equity ratio of 0.40. Wall Street Analysts Forecast Growth A number of research firms have recently commented on BIIB.
Wedbush cut their price objective on Biogen from $215.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, August 2nd.
Royal Bank of Canada boosted their target price on shares of Biogen from $282.00 to $292.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd.
Needham & Company LLC reaffirmed a “buy” rating and issued a $285.00 price target on shares of Biogen in a research note on Monday, August 19th. Truist Financial reiterated a “buy” rating and set a $302.
00 price objective (down from $340.00) on shares of Biogen in a research note on Monday, August 5th. Finally, Mizuho reduced their target price on shares of Biogen from $277.
00 to $251.00 and set an “outperform” rating for the company in a research report on Tuesday, August 6th. Eight equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock.
According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $276.35.
View Our Latest Report on BIIB Biogen Company Profile ( Free Report ) Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. See Also Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Biogen Inc. ( NASDAQ:BIIB – Free Report ). Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.
com's FREE daily email newsletter ..
